Company Overview and News

17
Discovery: An Unscripted Powerhouse With Global Reach

2018-10-04 seekingalpha
Discovery's stock price has recovered strongly this year, but there is still a lot of pessimism surrounding media companies.
CBS AMCX DISCA CMCSA NFLX DIS

1
Smaller media companies like Discovery and AMC probably won't find any buyers for a while

2018-09-24 cnbc
The biggest media companies still want to eat, but first, they're going to need a break to digest.
DISCB DISCA AMCX TWX DISCK TWC DISC

16
3 Cheap Stocks to Buy Before They Skyrocket

2018-09-17 investorplace
The S&P 500 has risen nearly 10% this year, but its increase over the past few years has had a substantial impact on valuations. Notably, ever since the S&P’s upward rise in 2009, the average price-earnings ratio has increased significantly, from just under 15.5 in 2010 to a high of over 25 today.
SNI DISCB DISCA NFLX DISCK CVS MU MS UNH ESRX DISC

3
Wednesday’s Biggest Winners and Losers in the S&P 500

2018-09-12 247wallst
September 12, 2018: The S&P 500 closed flat at 2,888.84. The DJIA closed flat at 25,997.84. Separately, the Nasdaq was down 0.2% at 7,954.23.
DISCA MU

 
Discovery Stock Surges on News of Hulu Partnership

2018-09-12 investorplace
The deal between Discovery (NASDAQ:DISCA) and Hulu will have the company bringing much of its content to the streaming service. This includes almost 4,000 episodes of some of the channels best shows.
DISCA

155
Stocks To Watch: Apple Event, Chinese Auto IPO To Headline

2018-09-08 seekingalpha - 2
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
KMT DISCB DISCA LBTY TWX LCII PGR DISCK IMAX CNK WMT IT LBTYK LILAB VIAB DOV BOX NWY TSM OCFC DISC VFC UPS NWS TTWO NWSA LAMR IEP OXM JNJ WIN LILAK VZ MBUU TLRD ALV.WI FARM HD KKR AIHS RCUS SSNLF TM ZS BWB NLSN CRTO WGO KLAC ATVI TEN JMBA SUOPY KR NWS AAPL AMTD BEN LYV CCI PSDO ATUS MCD CWH VIA GJV EA EVHC CMCSA LBTYB THO LBTYA RHP HMC CASY TGT S LPL T PLAY HPQ ATEYY LILA

15
Why Is Discovery (DISCA) Up 7.1% Since Last Earnings Report?

2018-09-06 zacks
It has been about a month since the last earnings report for Discovery Communications (DISCA - Free Report) . Shares have added about 7.1% in that time frame, outperforming the S&P 500.
SNI DISCB DISCA KHC DISCK FOSL DISC

153
Tracking George Soros's Portfolio - Q2 2018 Update

2018-09-02 seekingalpha - 15
Soros' 13F portfolio value increased from $6.16B to $6.25B this quarter. The number of positions decreased from 219 to 203.
VR LRCX DISCB DISCA NOW TWX DISCK INXN VICI CRM AMZN EQT AABA AET DISC BAC SIGM LGF KWN.CL UTX AIG TWC COUP CZR RNG XLGLF QCOM LIVN FG TIVO WFCNP TMO XL NFLX BAX BAC KW KWN CI GM LBRDB WFC EA C ZAYO CACQ COL LBRDK I TGT LIVN ETFC CNQ CVX LGF.A LBRDA LGF.B SBAC

57
The 10 Best Stocks to Buy for the Rest of 2018

2018-08-22 investorplace - 1
We’re halfway through 2018, and all the major market indices are beginning to rumble with breakout potential. Since mid-June, the S&P 500 is up roughly 7%, but only about 4% since the start of the year. But led by double-digit performances by Nike (NYSE:NKE), Apple (NASDAQ:AAPL) and Microsoft (NASDAQ:MSFT) in the Dow Jones, and 80%, 90% and 200% gains from the S&P’s best stocks to buy, the market is on the verge of shedding 2018’s correction.
STZ.B DISCB DISCA ULTA TWX STZ GOOG DISCK TWC FEYE AMZN NKE T GOOGL GRMN AAPL MSFT TXT DLX DISC

 
Discovery Communications (DISCA) Lags Q2 Earnings and Revenue Estimates

2018-08-07 zacks
Discovery Communications (DISCA - Free Report) just came out with quarterly earnings of $0.66 per share, missing the Zacks Consensus Estimate of $0.84 per share. This compares to earnings of $0.68 per share a year ago. These figures are adjusted for non-recurring items.
DISCB DISCA AMT DISCK NHI BCRX DISC GTLS

2
Facts to Know Ahead of News Corporation's (NWSA) Q4 Earnings

2018-08-06 zacks
News Corporation (NWSA - Free Report) is slated to report fourth-quarter fiscal 2018 results on Aug 9. The company outperformed the Zacks Consensus Estimate in all the trailing four quarters by an average of 79.6%. In the last reported quarter, this diversified media conglomerate delivered a positive earnings surprise of 20%. Let’s see how things are shaping up prior to this announcement. Which Way Are Top & Bottom-Line Estimates Headed? The Zacks Consensus Estimate for the quarter under review stands at 6 cents, reflecting a year-over-year decline of 45.
GJV FOX MKGAF DISCB DISCA NWSA DISCK BGSF AMCX MKGAY NWS FOXA DISC

 
ProSiebenSat.1 Media's (PBSFY) CEO Max Conze on Q2 2018 Results - Earnings Call Transcript

2018-08-04 seekingalpha
Good morning, ladies and gentlemen. Welcome to the Q2 and H1 2018 results call of ProSiebenSat.1 Media SE. This conference is being recorded. Today's call is hosted by Ms. Stefanie Rupp-Menedetter. Please go ahead.
DISCB DISCA NYTAB DISCK PBSFY DISC

 
Can Discovery (DISCA) Keep the Earnings Surprise Streak Alive?

2018-08-03 zacks
Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Discovery Communications (DISCA - Free Report) , which belongs to the Zacks Broadcast Radio and Television industry, could be a great candidate to consider.
DISCB DISCA DISCK DISC

64
Investment Humility And Economic Recovery

2018-08-01 seekingalpha - 2
We make every effort to understand the way that investors go to extremes over what we call the “well-known fact” in the stock market.
BAC DISCA CMCSA LEN AXP NVR LEN.B DIS

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: 25470F104